PERINATAL TRIALS REPORT

PT0357

CAP Trial

Caffeine for Apnea of Prematurity Trial.

Plain Language Summary:      The CAP trial is designed to test whether avoidance of methylxanthines (caffeine) in the prevention or treatment of apnoea of prematurity reduces the risk of adverse outcomes for infants weighing 500-999 grams at birth.

Trial status:                         Closed to accrual

Trial Objective:

Does overdose of methylxanthines improve infasnt survival in infants < 1250 grams?

Type of administration:        Multi-centre International

Principal Investigator/s:        Barbara Schmidt                                          

                                         Peter Davis

                                         Ph 61 3 9344 2000

                                         Email pgd@unimelb.edu.au

Contact Person/s:                Peter Davis

                                         Ph 61 3 9344 2000

                                         Email pgd@unimelb.edu.au

© IMPACT/PSANZ 2001